Corporate calendar for None (CGTX): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Price
| Price | $1.02 |
| Market Cap | $91M |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.86 |
Related companies: AGEN · ATOS · GLSI · IRD · MCRB · SEER · SPRO
More sections of CGTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks